EP2900662A1 - Procédé de préparation d'un sel de potassium d'azilsartan médoxomil hautement pur - Google Patents

Procédé de préparation d'un sel de potassium d'azilsartan médoxomil hautement pur

Info

Publication number
EP2900662A1
EP2900662A1 EP13779507.6A EP13779507A EP2900662A1 EP 2900662 A1 EP2900662 A1 EP 2900662A1 EP 13779507 A EP13779507 A EP 13779507A EP 2900662 A1 EP2900662 A1 EP 2900662A1
Authority
EP
European Patent Office
Prior art keywords
azilsartan medoxomil
solvate
dimethyl acetamide
potassium salt
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13779507.6A
Other languages
German (de)
English (en)
Inventor
Jan Stach
Radim Krulis
Josef Cerny
Ludek Ridvan
Ondrej Dammer
Lukas KREJCIK
Stanislav Radl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of EP2900662A1 publication Critical patent/EP2900662A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a method of preparation of the potassium salt of (5 -methyl oxo-l,3-dioxol-4-yl)methyl ester of l-[[2'-(2,5-dihydro-5-oxo-l,2 5 4-oxadiazol-3-yl)[l,l'- biphenyl]-4-yl]methyl]-2-ethoxy-lH-benzimidazole-7-carboxylic acid of formula (T)
  • azilsartan medoxomil (I), the synthesis of which is described in EP 1 718 641, EP 2 119 715, is used in the treatment of hypertension.
  • Azilsartan medoxomil is a "prodrug" that is easily enzymatically transformed to azilsartan, which is a highly selective antagonist of angiotensin II ATI receptors.
  • azilsartan medoxomil is prepared by a reaction of the free azilsartan acid with medoxomil alcohol, which provides azilsartan medoxomil as a solvate with dimethyl acetamide. This is then transformed, by crystallization of the product from an acetone/water mixture, to desolvated azilsartan medoxomil, which is subsequently converted to the potassium salt (I). Disclosure of Invention
  • This invention provides a method of preparing the potassium salt of azilsartan medoxomil of formula
  • a solvent which is dimethyl acetamide or N-methyl pyrrolidone or their mixtures with other solvents, is prepared, the resulting solvate is optionally re-crystallized, and, in the next step, converted, without desolvating, into the potassium salt using a potassium source.
  • the potassium source is, e.g., the potassium salt of 2-ethylhexanoic acid, and the solvent used for the conversion to the potassium salt is, e.g., acetone.
  • Azilsartan medoxomil (II) obtained in accordance with the patent EP 2 119 715 exhibits a maximum purity of 98.0% as determined by HPLC. Its desolvation according to the patent from an acetone/water mixture does not virtually achieve any further purification of the substance, nor does re-crystallization from an acetone/water mixture. Then, such raw material is not suitable for pharmaceutical production.
  • EP2 1 19 715 Azilsartan medoxomil Crystallized from a 90 % 99.77 % 0.03 % 0.09 % solvate with dimethyl dimethyl
  • both the solvates can also be prepared from a non-solvated form of azilsartan medoxomil by crystallization from dimethyl acetamide/isopropyl acetate or N- methyl pyrrolidone/isopropyl acetate mixtures, while the structurally similar dimethyl formamide does not form a solvate under these conditions.
  • Solid forms of azilsartan medoxomil can be described with methods commonly used for characterization of the solid phase, such as X-ray Powder Diffraction (XRPD), Differential Scanning Calorimetry (DSC).
  • a solvate of azilsartan medoxomil with dimethyl acetamide (1 :1) exhibits the following main characteristic peaks in the X-ray Powder Diffraction measured, with the use of CuKa radiation: 11.0; 12.1 ; 17.2, 25.3 ⁇ 0.2° 2theta, and further the following other characteristic peaks: 11.8; 19.5; 22.2; 24.3 ⁇ 0.2° 2theta.
  • Table 2 XRPD - characteristic diffraction peaks corresponding to a solvate of azilsartan medoxomil with dimethyl acetamide.
  • a solvate of azilsartan medoxomil with dimethyl acetamide can be prepared by crystallization from dimethyl acetamide and another solvent in which azilsartan medoxomil only dissolves to a limited extent, such as isopropyl acetate, isobutyl acetate, ethyl acetate, methyl acetate, acetone, methyl ethyl ketone and methyl isobutyl ketone. Crystallization is carried out at a temperature in the range of from 10°C to 100°C.
  • the potassium salt of azilsartan medoxomil is characterized by the following main peaks, measured with the use of CuKa radiation: 6.15°, 13.96°, 18.72° and 21.37° 2 ⁇ ⁇ 0.2° 2 ⁇ .
  • the characteristic XRPD peaks are presented in Table 3.and an XRPD record in Fig. 1. This form is further characterized with a Differential Scanning Calorimetry (DSC) record, see Fig.2.
  • a solvate of azilsartan medoxomil with N-methyl pyrrolidone is characterized by the following main characteristic peaks in an X-ray Powder record, measured with the use of CuKa radiation: 10.9; 16.3; 17.2; 18.9; ⁇ 0.2° 2theta.
  • the characteristic XRPD peaks are presented in Table 4 and the XRPD record in Fig 5. This form is further characterized with a Differential Scanning Calorimetry (DSC) record, see Fig. 6.
  • DSC Differential Scanning Calorimetry
  • Table 4 XRPD - characteristic diffraction peaks corresponding to a solvate of azilsartan medoxomil with N-methyl pyrrolidone.
  • a solvate of azilsartan medoxomil with N-methyl pyrrolidone can be prepared by crystallization from N-methyl pyrrolidone and another solvent in which azilsartan only dissolves to a limited extent, such as isopropyl acetate, isobutyl acetate, ethyl acetate, methyl acetate, acetone, methyl ethyl ketone and methyl isobutyl ketone. Crystallization is carried out at a temperature in the range of from 10°C to 100°C.
  • Fig. 1 X PD record for the potassium salt of azilsartan medoxomil
  • Fig. 2 DSC record for the potassium salt of azilsartan medoxomil
  • Fig. 3 XRPD record for a solvate of azilsartan medoxomil with dimethyl acetamide
  • Fig. 4 DSC record for a solvate of azilsartan medoxomil with dimethyl acetamide
  • Fig. 5 XRPD record for a solvate of azilsartan medoxomil with N-methyl pyrrolidone
  • Fig. 6 DSC record for a solvate of azilsartan medoxomil with N-methyl pyrrolidone
  • Soller diaphragms 0.02 rad and an anti-dispersion diaphragm 1 ⁇ 4 were used.
  • Soller diaphragms 0.02 rad and an anti-dispersion diaphragm 5.0 mm were used.
  • the Differential Scanning Calorimetry (DSC) records were measured with a DSC Pyris 1 device made by Perkin Elmer.
  • the charge of the sample in a standard Al pot was between 3-4 mg and the heating-up rate was 10°C/min.
  • the temperature program used consists of 1 minute of stabilization at the temperature of 50°C and then of heating to 250°C at the heating-up rate of 10°C/min.
  • As the carrier gas 4.0 N 2 was used at the flow of 20 ml/min.
  • Example 4 Preparation of azilsartan medoxomil as a solvate with dimethyl acetamide Crude azilsartan medoxomil prepared in accordance with Example 2 was dissolved in a mixture of dimethyl acetamide (4 ml) with isopropyl acetate (6 ml) in a hot state; after cooling and aspiration, 3.6 g (90 %) of the product was obtained, HPLC purity 99.77 %.
  • Example 5 Preparation of azilsartan medoxomil as a solvate withN-methyl pyrrolidone Crude azilsartan medoxomil prepared in accordance with Example 2 was dissolved in a mixture of N-methyl pyrrolidone (4 ml) with isopropyl acetate (7 ml) in a hot state; after cooling and aspiration, 2.8 g (69 %) of the product was obtained, HPLC purity 99.84 %.
  • Example 6 Preparation of the potassium salt of azilsartan medoxomil
  • Example 8 Preparation of the ethyl ester of 2-ethoxy-l-((2'-(5-oxo-4,5-dihydro-l,2,4- oxadiazol-3-yl)biphenyl-4-yl)methyl)-lH-benzo[i/]-imidazole-7-carboxylic acid (V).
  • the starting amidoxime (IV) was suspended in diethyl carbonate (30 g) and sodium ethoxide (21 % in ethanol, 9 g) was added. The mixture was heated at 80°C for 2h, 20 ml of the solvent was removed by distillation, ethanol (20 ml), water (20 ml) and acetic acid (3 g) and more water (20 ml) were added. The suspension was stirred at 50°C for 1 h and cooled to 25°C. 8 g (76 %) of the product was obtained.
  • the starting ethyl ester of azilsartan (V, 250 g) was suspended in a solution of sodium hydroxide in water (56 g/800ml). The suspension was heated at 50°C for 4 h, after pH adjustment to 4-5, the product crystallized providing 232 g (98.5 %).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)

Abstract

L'invention porte sur un procédé de préparation du sel de potassium d'azilsartan médoxomil de formule I, suivant lequel un solvate d'azilsartan médoxomil de formule II, avec un solvant choisi dans le groupe constitué par le diméthylacétamide, la N-méthylpyrrolidone ou leurs mélanges avec d'autres solvants, est préparé, ou recristallisé à partir de diméthylacétamide, de N-méthylpyrrolidine ou leurs mélanges avec d'autres solvants et, dans l'étape suivante, converti en le sel de potassium à l'aide d'une source de potassium dans un solvant approprié.
EP13779507.6A 2012-09-26 2013-09-25 Procédé de préparation d'un sel de potassium d'azilsartan médoxomil hautement pur Withdrawn EP2900662A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2012-663A CZ305318B6 (cs) 2012-09-26 2012-09-26 Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu
PCT/CZ2013/000114 WO2014048404A1 (fr) 2012-09-26 2013-09-25 Procédé de préparation d'un sel de potassium d'azilsartan médoxomil hautement pur

Publications (1)

Publication Number Publication Date
EP2900662A1 true EP2900662A1 (fr) 2015-08-05

Family

ID=66624776

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13779507.6A Withdrawn EP2900662A1 (fr) 2012-09-26 2013-09-25 Procédé de préparation d'un sel de potassium d'azilsartan médoxomil hautement pur

Country Status (12)

Country Link
EP (1) EP2900662A1 (fr)
JP (1) JP2015532267A (fr)
KR (1) KR20150060733A (fr)
CN (1) CN104662019A (fr)
BR (1) BR112015006572A2 (fr)
CZ (1) CZ305318B6 (fr)
EA (1) EA028171B1 (fr)
HK (1) HK1205505A1 (fr)
IL (1) IL237884A0 (fr)
MX (1) MX2015003209A (fr)
UA (1) UA113668C2 (fr)
WO (1) WO2014048404A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2014702A3 (cs) * 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
CN105753854A (zh) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 一种阿齐沙坦酯钾盐的新制备方法
CN109071519A (zh) * 2016-01-28 2018-12-21 株式会社德山 阿齐沙坦及其制造方法
CN108727356A (zh) * 2018-06-28 2018-11-02 江苏新瑞药业有限公司 一种奥美沙坦酯碱金属盐的合成方法
CN115894472B (zh) * 2022-12-14 2025-08-19 仁合益康集团有限公司 一种高纯度阿齐沙坦酯钾盐的制备方法
CN117126150A (zh) * 2023-08-29 2023-11-28 仁合益康集团有限公司 一种阿齐沙坦酯钾盐杂质a的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157584B2 (en) 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
WO2012090043A1 (fr) * 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Nouvelles formes à l'état solide d'azilsartan médoxomil et leur procédé de préparation
EP2673274B1 (fr) * 2011-02-08 2019-07-17 Jubilant Generics Limited Procédé amélioré pour la préparation d'azilsartan médoxomil
WO2013042067A1 (fr) * 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Procédé de préparation d'un sel de potassium de l'azilsartan médoxomil
US9403811B2 (en) * 2012-01-14 2016-08-02 Sunshine Lake Pharma Co., Ltd. Crystalline forms of azilsartan medoxomil potassium and preparation and uses thereof
CZ2012274A3 (cs) * 2012-04-19 2013-10-30 Zentiva, K.S. Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2014048404A1 *

Also Published As

Publication number Publication date
WO2014048404A1 (fr) 2014-04-03
BR112015006572A2 (pt) 2017-07-04
IL237884A0 (en) 2015-05-31
CZ2012663A3 (cs) 2014-04-02
HK1205505A1 (en) 2015-12-18
UA113668C2 (uk) 2017-02-27
KR20150060733A (ko) 2015-06-03
CN104662019A (zh) 2015-05-27
JP2015532267A (ja) 2015-11-09
EA028171B1 (ru) 2017-10-31
MX2015003209A (es) 2015-07-14
EA201590657A1 (ru) 2015-08-31
CZ305318B6 (cs) 2015-07-29

Similar Documents

Publication Publication Date Title
CA2958625C (fr) Cristal de dipyrromethene et son procede de fabrication
US20210188813A1 (en) Ezh2 inhibitor and pharmaceutically acceptable salts and polymorphic substances thereof, and application of ezh2 inhibitor
WO2014048404A1 (fr) Procédé de préparation d'un sel de potassium d'azilsartan médoxomil hautement pur
US9624207B2 (en) Polymorphs of azilsartan medoxomil
CA3059394C (fr) Preparation de derives de l'acide 2-([1,2,3]triazol-2-yl)-benzoique
KR101275092B1 (ko) 아질사르탄의 개선된 제조방법
US9695147B2 (en) Process for the preparation of perampanel
EP2872499A1 (fr) Procédé de préparation d'intermédiaires pour la synthèse d'étexilate de dabigatran, et formes cristallines de ces intermédiaires
WO2018008219A1 (fr) Intermédiaire d'azilsartan, azilsartan, procédé de production d'un intermédiaire d'azilsartan et procédé de production d'azilsartan
WO2013156005A1 (fr) Procédé de préparation d'un sel de potassium d'azilsartan médoxomil de grande pureté
KR102891811B1 (ko) 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의 고체 형태
JP2017535533A (ja) 高純度のアジルサルタンを調製するための方法
KR20240038023A (ko) 식 i의 화합물의 결정형 및 이의 제조와 응용
JP2014530248A (ja) ボセンタンの酸付加塩
JP2018076258A (ja) アジルサルタンアルキルエステル、アジルサルタンメチルエステルの製造方法、及びアジルサルタンの製造方法
EP2870151A2 (fr) Nouveaux polymorphes d'azilsartan
JP2018197206A (ja) アジルサルタン合成中間体の製造方法
JP2010100562A (ja) アムロジピン製造中間体の精製方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150307

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

17Q First examination report despatched

Effective date: 20170301

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180404